InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,620.85
(
0.42%
)
US TECH 100
19,332.00
(
0.63%
)
Dow Jones
40,890.49
(
0.14%
)
Brent Oil
75.63
(
-0.08%
)
Bitcoin
61,180.00
(
0.00%
)
Post# of 252939
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 837
Posts 120317
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jshaffer85 post# 20549

Thursday, 12/15/2005 10:56:59 AM

Thursday, December 15, 2005 10:56:59 AM

Post# of 252939
Re: KOSP

>Yes. A license for that component of their combination pill.<

I was assuming that MRK could make its own ER pill without violating KOSP’s composition-of-matter patents. Hence, the IP license I was suggesting would be for an ER Niacin pill’s use for specified medical conditions.

In answer to your question about when MRK would need to take a license, they could wait until after phase-3, or even until after commercialization before deciding what terms to agree to (or whether to take no license and risk litigation).

I am not at all well-versed in KOSP’s IP, so I’m just speculating here. Perhaps our resident KOSP expert, shears, will chime in.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up